目的 观察老年冠心病患者小血管置入国产EXCEL支架的安全性与有效性。
Abstract
Objective To assess the efficacy and safety of percutaneous coronary intervention with EXCEL stents for elderly patients with small vessel coronary artery disease. Methods Patients were assigned into small stent group(<3 mm,297patients) and larger stent group (≥3 mm,405 patients). The pre-specified primary outcome was the rate of major adverse cardiac events (MACE) at 6, 12 and 18 months. Results At 6 to 18 months, there was no significant difference between the two groups in MACE,stent thrombosis or Cardiac death (P>0.05).The small stent group had higher stent thrombosisrate than the large stent group（P<0.05）. Conclusions This study demonstrates not only the clinical safety and efficacy of biodegradable polymer based sirolimus-eluting stents. in elderly patients with small vessel coronary artery disease,but also a higher stent thrombosis rate in the long-term outcome.
关键词
小血管 /
EXCEL支架 /
经皮冠状动脉介入治疗
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
［1］ Mehilli J, Kastrati A, Dirschinger J, et al. Comparison of stenting with balloon angioplasty for lesions of small coronary vessels in patients with diabetes mellitus ［J］. The American journal of medicine, 2002,112(1):13-18.
[2] Germing A, Dryander S, Machraoui A, et al. Coronary artery stenting in vessels with reference diameter< 3 mm［J］. Journal of Interventional Cardiology, 2000,13(5):309-314.
[3] Koh A S, Chia S, Choi L M, et al. Long-term outcomes after coronary bare-metal-stent and drug-eluting-stent implantations: a real-world comparison among patients with diabetes with diffuse small vessel coronary artery disease［J］. Coronary Artery Disease, 2011,22(1):96-101.
[4] Lagerqvist B, James S K, Stenestrand U, et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden［J］. N Eng J Med, 2007,356(10):1009-1019.
[5] Elezi S, Kastrati A, Pache J, et al. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement［J］. JACC, 1998,32(7):1866-1873.
[6] Pfisterer M, Brunner-La Rocca H P, Buser P T, et al. Late Clinical Events After Clopidogrel Discontinuation May Limit the Benefit of Drug-Eluting Stents: An Observational Study of Drug-Eluting Versus Bare-Metal Stents［J］. JACC, 2006,48(12):2584-2591.
[7] Luscher T F, Steffel J, Eberli F R, et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications［J］. Circulation, 2007,115(8):1051-1057.
[8] Han Y, Jing Q, Li Y, et al. Sustained clinical safety and efficacy of abiodegradable polymer coated sirolimus eluting stent in real world practice: 3 year outcomes of the CREATE (multi center registry of EXCEL biodegradable polymer drug eluting stents) study［J］. Catheterization and Cardiovascular Interventions, 2011,105(8):1005-1009.
[9] Hermiller J B, Fergus T, Pierson W, et al. Clinical and angiographic comparison of everolimus-eluting and paclitaxel-eluting stents in small coronary arteries: a post hoc analysis of the SPIRIT III randomized trial［J］. American heart journal, 2009,158(6):1005-1010.
[10] Schofer J, Schluter M, Gershlick A H, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS)［J］. Lancet, 2003,362(9390):1093-1099.
[11] Pfisterer M, Brunner L A, Buser P, et al. BASKET-LATE Investigators, Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents［J］.JACC, 2006,48(12):2584-2591.
[12] Eeckhout E,Kappenberger L,Goy J J. Stents for intracoronary placement: current status and future directions ［J］.JACC, 1996,27(4):757-765.
PDF(636 KB)
